- Martin Eccles (Martin.Eccles@ncl.ac.uk), professor of clinical effectivenessa,
- Nick Freemantle, senior research fellowb,
- James Mason, research fellowb,
- the North of England Aspirin Guideline Development Group.
- a Centre for Health Services Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4AA
- b Centre for Health Economics, University of York, York YO1 5DD
- Correspondence to: Professor Eccles
- Accepted 16 December 1997
Patients who have had cardiovascular disease and stroke are treated with aspirin to reduce their subsequent risk of vascular events or death and thereby to increase the length and quality of their life. This guideline aims to provide general practitioners with evidence linked recommendations on the use of aspirin as secondary prophylaxis for cardiovascular disease and stroke in patients at high risk of these disorders. It is assumed that doctors will use their knowledge and clinical judgment in managing individual patients in the light of available resources. Recommendations may not be appropriate for use in all circumstances. This is a summary of the full version of the guideline.1
Summary points
The use of aspirin in the secondary prophylaxis of vascular disease is cost effective
Aspirin should be used in patients with acute myocardial infarction, prior myocardial infarction, stable and unstable angina, and prior stroke or transient ischaemic attack
In acute myocardial infarction a dose of 150 mg daily should be used
In the other indications a dose of 75 mg daily should be used
Incidence
In general practice, patients with a raised risk of vascular disease present with several disorders—acute or previous myocardial infarction, unstable or stable angina, transient ischaemic attacks, and peripheral vascular disease. The incidence and prevalence of these conditions and the workload associated with them in general practice can be estimated from the recent national morbidity survey in general practice for England and Wales, and is shown in the table.2
- In this window
- In a new window
Diseases associated with a raised risk of vascular events—incidence, prevalence, and workload in a general practice, assuming a list size of 2000 patients
Categorising evidence
Throughout this guideline the strength of statements on evidence and of recommendations is categorised according to the scheme discussed in the first paper in the series.3 The box below shows these categories in descending …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012